Barely Significant
← all excerpts

Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild-type KRAS exon 2 metastatic colorectal cancer.

Cancer Med · 2019 · PMC6601597 · PMID 31090176

Europe PMCDOI
1
hedged sentence
0.0610
closest p · 1.2× alpha
0.0610
boldest claim

The sentences

marginal significanceP = 0.061so close (0.05 < p ≤ 0.1)
The cetuximab → bevacizumab group also had longer OS than the bevacizumab → cetuximab group among patients with right‐sided tumors with marginal significance (HR: 95% CI:, P = 0.061), which is contradictory to the relationship between sidedness and EGFR first‐line treatment efficacy elucidated in several randomized trials. 29 This might be attributable to selection bias in our study, in that patients with right‐sided colon tumors that had higher surviva

also in 4,564 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.